April 15, 2026 01:12 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'ECI deviated from Bihar procedure': Supreme Court raises concerns over voter deletion in Bengal SIR | Noida workers’ protest turns violent: Stones pelted, vehicles damaged over wage hike demand | Oil prices jump above $103 a barrel as US moves to block Iran-linked shipping | I don’t care if they come back or not, says Trump after Iran talks collapse | Legendary singer Asha Bhosle suffers cardiac arrest, hospitalised | Big boost to India–Mauritius ties: S. Jaishankar hands over 90 e-buses | Middle East tension: Iranian delegation arrives in Islamabad for major talks, 10,000 security personnel deployed | Ranveer Singh visits RSS HQ amid Dhurandhar 2 success, triggers speculation | ED raids ex-Bengal minister Partha Chatterjee; SSC scam resurfaces ahead of polls | Amit Shah promises UCC, ₹3,000 aid per month for women and youth in BJP’s Bengal manifesto
COVID19
Unsplash

US drug agency says COVID-19 vaccine may be authorized before end of phase 3 trials

| @indiablooms | Aug 31, 2020, at 03:09 am

Washington/Sputnik: The US Food and Drug Administration (FDA) is ready to authorize a vaccine against COVID-19 before the end of phase three clinical trials if such a move proves to bring more benefits than risks, Stephen Hahn, the head of the FDA, told the Financial Times (FT) in an interview, which was published on Sunday.

At the moment, three pharmaceutical companies, namely AstraZeneca, Moderna and Pfizer, are conducting phase three trials in the United States, and President Donald Trump has said that vaccine could be approved in the country before the November 3 presidential election. Hahn told the FT that the FDA was ready to bypass the usual process for a vaccine authorization but would not do so just to please the president.

"It is up to the sponsor to apply for authorization or approval, and we make an adjudication of their application … If they do that before the end of Phase Three, we may find that appropriate. We may find that inappropriate, we will make a determination," Hahn said, adding that the FDA’s authorization was possible if "the benefit outweighs the risk in a public health emergency."

The FDA head also mentioned that the agency’s authorization for the emergency use of a potential vaccine did not equal its full approval.

At the same time, Hahn said that FDA’s decisions would be based on science and medicine, and not on politics or the upcoming election.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.